Clinical Pharmacology & Therapeutics · 2014 · 107 citations · 28 references
MedicinePharmacokineticsPharmacologyClinical PharmacologyPharmacogeneticsPharmacogenomicsBlood Pressure ManagementHypertension ManagementHypertension PharmacotherapyPharmacogenomics In CardiologyBlood PressureCyp2d6 Drug MetabolismCyp2d6 GenotypeCyp2d6 GenotypingCyp2d6 PharmacogeneticsCyp2d6 PhenotypingCytochrome P450 2D6Cytochrome P450 Enzyme Activity
Metoprolol is a selective β-1 adrenergic receptor blocker that undergoes extensive metabolism by the polymorphic enzyme cytochrome P450 2D6 (CYP2D6). Our objective was to investigate the influence of CYP2D6 polymorphisms on the efficacy and tolerability of metoprolol tartrate. Two hundred and eighty-one participants with uncomplicated hypertension received 50 mg of metoprolol twice daily followed by response-guided titration to 100 mg twice daily. Phenotypes were assigned based on results of CYP2D6 genotyping and copy number variation assays. Clinical response to metoprolol and adverse effect rates were analyzed in relation to CYP2D6 phenotypes using appropriate statistical tests. Heart rate response differed significantly by CYP2D6 phenotype (P < 0.0001), with poor and intermediate metabolizers showing greater reduction. However, blood pressure response and adverse effect rates were not significantly different by CYP2D6 phenotype. Other than a significant difference in heart rate response, CYP2D6 polymorphisms were not determinants of variability in metoprolol response or tolerability.
28
2013 ACCF/AHA Guideline for the Management of Heart Failure
Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt et al. · Journal of the American College of Cardiology · 2013 · 12.6K citations
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
Patrick T. O’Gara, Frederick G. Kushner, Deborah D. Ascheim et al. · Circulation · 2012 · 4.7K citations